

1st Edition

CRCM Symposium

CANCER RESEARCH CENTER MARSEILLE



4 - 6
February
2026

CONFIRMED SPEAKERS

Frédéric Bard (*Marseille, France*)
Martin Bergö (*Stockholm, Sweden*)
René Bernards (*Amsterdam, The Netherlands*)
François Bertucci (*Marseille, France*)
Brice Chanez (*Marseille, France*)
Raffaele Colombo (*Vancouver, Canada*)
Nelson Dusetti (*Marseille, France*)
Greta Mattavelli (*Germany*)
Patrick Mehlen (*Lyon, France*)
Gérard Milano (*Nice, France*)
Javad Nazarian (*Zurich, Switzerland*)
Angela Nieto (*Alicante, Spain*)
Thales Papagiannakopoulos (*New York, USA*)
Gabriel Revon-Riviere (*Marseille, France*)
Giorgio Seano (*Paris, France*)
Sophie Tartare-Deckert (*Nice, France*)
Alissa Weaver (*Nashville, USA*)
Mattia Zampieri (*Basel, Switzerland*)

ORGANIZING COMMITTEE

Joseph Cicolini, Nelson Dusetti, Christophe Ginestier,
Luca Lignitto, Emilie Mamessier, Eddy Pasquier, Sophie Vasqueur

With the valuable support of the junior researchers:

Agathe Cohendet, Georgios Efthymiou, Julie Lafont, Raphael Leblanc,
Shuheng Lin, Maëlle Picard, Celia Sequera-Hurtado, Romain Zakrajsek

MARSEILLE
Palais du Pharo

TOPICS/SESSIONS

Innovative therapies
Tumor microenvironment & cellular cross-talk
Challenging sites of tumorigenesis: junior scientist session
Cancer progression and treatments



VILLE DE
MARSEILLE



This event is supported by the City of Marseille.

1st Edition

CRCM Symposium

CANCER RESEARCH CENTER MARSEILLE



Comet
Cell communication & Microenvironment dist.

Translate-IT
Translational research & innovative therapies dist.

4 - 6
February
2026

MARSEILLE
Palais du Pharo

EDITO

Dear Congress members, Dear participants, Dear Colleagues,

Welcome to Marseille,

We have the pleasure and the honor to invite you to participate at the first edition of the CRCM Symposium (Centre de Recherche en Cancérologie de Marseille) that emerges with a biannual intention.

Since 2008, CRCM scientists including 450 people and 21 teams, has been developing programs of basic and clinical research, with the unchanging desire to transfer fundamental data to the clinic, the « benchside to bed » principle that constitutes the foundation of our institution to make significant breakthroughs and improve the therapeutic management of cancer patients.

The symposium is organized around the scientific topics represented by two departments of CRCM: Comet (Cell Communication and Microenvironment) and Translate-IT (Translational research and Innovative therapies).

During these two days and a half, we gathered an exceptional program with diverse and state of the art sessions with special focus on tumour microenvironment and cellular crosstalk, based on metabolic and extra-vesicular communication, nanotechnologies, tumor cell signaling and pharmacologic innovations.

The Palais du Pharo will constitute a privileged venue to host the invited national and international keynote and lecture speakers with outstanding expertise in the cancerology domain. We are convinced that the surroundings and striking views of the Mediterranean and the Old Port, will be an additional incentive to participate in this extraordinary opportunity to build up new collaborations and favour exchanges with researchers and speakers.

Note the date in your agendas, we are looking forward to host many of you for this first session and specially encourage young scientists to register.

The Scientific and Organizing Committee

PROGRAM

WEDNESDAY FEBRUARY 4

16:00-16:30	General introduction.
16:30-17:20	 Keynote Moderators: Joseph CICCOLINI, Nelson DUSETTI (Marseille, France) Innovative approaches to combat cancer drug resistance. René BERNARDS (Amsterdam, The Netherlands) Netherlands Cancer Institute, Amsterdam
17:20-18:10	 Keynote Moderators: Christophe GINESTIER, Sophie VASSEUR (Marseille, France) Exosomes in Cancer Aggressiveness. Alissa WEAVER (Nashville, USA) Vanderbilt University School of Medicine
18:10-20:00	Bridging science and patients' community (session in french) Flash talks (public-friendly presentations of scientific projects). Wine and cheese + award best presentation.
18:10	
18:40	

THURSDAY FEBRUARY 5

09:00-09:10	Welcome words
09:10-10:30	SESSION 1: Innovative Therapies - New therapies Moderators: Joseph CICCOLINI, Anne RODALLEC (Marseille, France)
09:10	 Keynote - Antibody Drug Conjugates: Facts & Fiction. Raffaele COLOMBO (Vancouver, Canada) Zymeworks
10:00	 Lecture - Old wine in a New Bottle: Protacs in Oncology. Gérard MILANO (Nice, France) Centre Antoine Lacassagne, Nice, France
10:30-11:00	Coffee Break
11:00-13:00	SESSION 1: Innovative Therapies - Therapy resistance and tumor plasticity Moderators: Jeremy ARIEY-BONNET, Emilie MAMESSIER (Marseille, France)
11:00	 Lecture - Targeting glioblastoma cell state transitions induced by chemoradiation or neurosurgery. Giorgio SEANO (Paris, France) Institut Curie, Paris-Orsay
11:30	 Lecture - Deciphering drug modes of action by high-throughput metabolic profiling. Mattia ZAMPIERI (Basel, Switzerland) University of Basel
12:00	 Lecture - Exploring therapy resistance in pancreatic cancer through transcriptomic signatures. Nelson DUSETTI (Marseille, France) CRCM Cancer research center, Marseille
12:30	 Lecture - Drug-conjugated antibodies: when targeting meets chemotherapy. François BERTUCCI (Marseille, France) Institut Paoli Calmettes and CRCM
13:00-14:30	Lunch Break - Posters Sessions 1 (p7-8)

PROGRAM

THURSDAY FEBRUARY 5	
14:30-15:50	SESSION 2: Tumor microenvironment and cellular cross-talk Moderators: Georgios EFTHYMIU, Sophie VASSEUR (Marseille, France)
14:30	 <p>Keynote - Redox regulation of cancer metastasis. Martin BERGO (Stockholm, Sweden) Karolinska Institutet</p>
15:20	 <p>Lecture - Metabolic Mechanisms of Lung Cancer Progression. Thales PAPAGIANNAKOPOULOS (New York, USA) New York University Grossman School of Medicine</p>
15:50-16:20	Coffee Break
16:20-18:20	SESSION 2: Tumor microenvironment and cellular cross-talk Moderators: Celia SEQUERA HURTADO, Richard TOMASINI (Marseille, France)
16:20	 <p>Lecture - Role of melanoma cell plasticity in extracellular matrix remodeling and therapy resistance Sophie TARTARE-DECKERT (Nice, France) The Mediterranean Centre for Molecular Medicine (C3M)</p>
16:50	<p>Oral communications (selected abstracts)</p> <p>CO01 Assessing the spatial interplay of Tumor Heterogeneity and its microenvironment in Breast Cancer. Zeinab Homayed (CRCM, Marseille)</p>
17:05	<p>CO02 A humanized in vitro model to explore neuron-cancer interactions. Terarina Flavie Chung Shing (Institute of Developmental Biology of Marseille, France)</p>
17:20	 <p>Lecture - GALNT relocalisation reshapes the glycoproteome in pancreatic cancer and activates Integrin Beta 1. Frédéric Bard (Marseille, France)</p>
17:50	<p>Oral communications (selected abstracts)</p> <p>CO03 - Evaluation of the predictive value of Organoid-derived Extracellular Vesicles for tumor progression and Microenvironment-mediated resistance to FOLFIRINOX. Christopher Rovera (CRCM, Marseille)</p>
18:05	<p>CO04 Metastatic potential of colorectal cancer is regulated by an EphA2-PTK7 crosstalk. Charlotte Dessaux (CRCM, Marseille)</p>
19:30	Congress Dinner

PROGRAM

FRIDAY FEBRUARY 6	
08:30-10:20	SESSION 3: Challenging sites of tumorigenesis: junior scientist session Moderators: Giada FIANCADA, Eddy PASQUIER (Marseille, France) 
08:30	 Keynote - Understanding the biology of childhood high-grade gliomas: from knowledge gaps to therapeutic opportunities. Javad NAZARIAN (Zurich, Switzerland) University of Zürich / University Children's Hospital
09:20	Oral communications (selected abstracts) CO05 High-throughput drug screening reveals metabolic vulnerabilities in patient-derived diffuse midline glioma models. Julie Lafont (CRCM, Marseille)
09:35	CO06 Molecular heterogeneity, a key component in glioblastoma cells molecular dynamics under metabolic pressure. Mélanie Laurent-Blond (CRCI2NA UMR1307, Nantes, France)
09:50	 Lecture - Navigating innovative tools and therapies for children and adolescents with cancer (experience at Timone Children's Hospital, Marseille). Gabriel REVON-RIVIERE (Marseille, France)
10:20-10:50	Coffee Break
10:50-12:20	SESSION 3: Challenging sites of tumorigenesis: junior scientist session Moderators: Raphaël LEBLANC, Maelle PICARD (Marseille, France) 
10:50	 Lecture - Understanding the link between immune evasion and metastasis: A story of stromal - immune cell interactions in tumor-draining lymph nodes Greta MATTAVELLI (Germany) University of Würzburg
11:20	Oral communications (selected abstracts) CO07 Tuft cells remodel the mucosal immune microenvironment to promote intestinal tumorigenesis. Imène Gasmi (IGF, Montpellier)
11:35	CO08 BRD4 inhibition creates a permissive state for breast cancer initiation. Anaïs Grandon (CRCM, Marseille)
11:50	CO09 Investigating tumor-trained immunity in pancreatic cancer. Fanny Matrand (CRCM, Marseille)
12:05	CO10 Model-driven scheduling of nanocarriers: application to an anticancer polymer prodrug administered subcutaneously. Anne Rodallec (CRCM, Marseille)
12:20-14:00	Lunch Break & Posters Sessions 2 (p8-9)

PROGRAM

FRIDAY FEBRUARY 6	
14:00-17:00	SESSION 4: Cancer progression and treatments Moderators: Emmanuelle CHARAFE, Luca LIGNITTO (Marseille, France)
14:00	 <p>Keynote - Cancer cell plasticity trajectories in the primary tumor and to the metastatic site. Angela NIETO (Alicante, Spain) Instituto de Neurociencias (CSIC-UMH)</p>
14:50	<p>Oral communications (selected abstracts) CO11 Single-cell analysis of treatment-associated dynamics in PDAC reveals drug-response programs and plasticity mechanisms driving chemoresistance. Nicolas Fraunhofer (CRCM, Marseille)</p>
15:05	 <p>Lecture - Transcriptomic signature of response in PDAC : from bench to clinical trial. Brice CHANEZ (Marseille, France) Institut Paoli Calmettes et CRCM</p>
15:35	<p>Oral communications (selected abstracts) CO12 ORGANOTREAT-01: a pioneering multicenter trial of organoid-driven precision medicine in refractory colorectal cancers. Jerome Carry (Paris, France)</p>
15:50	 <p>Lecture - Targeting netrin-1 in oncology: from a cell biology hypothesis to clinical data. Patrick MELHEN (Lyon, France) Research Cancer Center of Lyon (CRCL)</p>
16:20	Poster / Talk prizes
17:00	Closing words

POSTERS SESSION 1

THURSDAY FEBRUARY 5 - 13H00-14H30

Precision oncology, targeted therapies and strategies for refined drug delivery

S1CA01: XON11: a novel multimodal polyclonal antibody to overcome tumor heterogeneity in pancreatic cancer. Ophélie Dauphouy (Nantes)	S1CA15: Combinatorial effects of romidepsin with inhibitors of anti-apoptotic signals on hepatocellular carcinoma and its immune microenvironment. Filippo Castagna (Marseille)
S1CA02: Identification of a fibroblast subtype associated with early-relapse in metastatic colorectal cancer by single-nuclei rna sequencing. Maelle Picard (Marseille)	S1CA16: Targeting MINK1 in triple negative breast cancer with a kinase inhibitor. Giulia Delacourt (Marseille)
S1CA03: Disarming radioresistant breast cancer cells by targeting yap pathway. Claire Zobouyan (Marseille)	S1CA17: UBE2N inhibition to sensitize ovarian cancers to PARP inhibitors by induction of HRD phenotype. Léonie Ibazizene (Caen)
S1CA04: Dendrimer nanosystems hijack in situ tumor-secreted extracellular vesicle for RNA delivery. Christina Galanakou (Marseille)	S1CA18: Which antibody-drug conjugate with limited off-target toxicities can be used to treat metastatic colorectal cancer? Lisa Malard (Marseille)
S1CA05: Uncovering Stage-Specific Vulnerabilities in Recurrent Breast Tumors. Emma Der Kazarian (Marseille)	S1CA19: Physiologically Relevant Drug Screening in PDAC Using Organoid-CAF Co-cultures. Jérémy Ariey-Bonnet (Marseille)
S1CA06: Identifying Therapeutic Vulnerabilities in Drug-Tolerant Persister Cells of Triple-Negative Breast Cancer Through Boolean Network Inference. Min Wu (Marseille)	S1CA20: Trastuzumab deruxtecan (T-DXd) as a new therapeutic option in pancreatic ductal adenocarcinoma (PDAC). Chiara Dall'ara (Milan, Italy)
S1CA07: Validation and molecular study of new ubiquitination type theranostic markers in pancreatic cancer. Hery Dinah Ratovonindrina (Marseille)	S1CA21: Use case of the EPITHOR database in the LUCA-pi project. Romain Zakrajsek (Marseille)
S1CA08: Identification and characterization of atypical circulating cells during neoadjuvant chemotherapy in early breast cancer patients. Agathe Cohendet (Marseille)	S1CA22: Combination therapy with YAP/TEAD and RAS inhibitors overcomes phenotypic cell plasticity-driven resistance in NRAS-mutated melanoma. Mira Kahil (Nice)
S1CA09: Combining innate V62 and CAR-mediated targeting to overcome glioblastoma heterogeneity. Julianne Ceroni (Nantes)	S1CA23: MET and SRC kinases promote NRF2 activity in Triple-Negative Breast Cancer: a novel vulnerability to enhance Paclitaxel sensitivity. Irene Taddei (Rome, Italy)
S1CA10: Cadherin X: new target to fight pancreatic cancer ? Amandine Lopez (Marseille)	S1CA24: Establishment of a mouse hepatocellular carcinoma tumoroid panel recapitulating inter- and intra-tumour heterogeneity for disease modelling and combinatorial drug discovery. Nicolas Pons (Marseille)
S1CA11: Bispecific engineered aptamers for ADAMTSL5 silencing confer druggable AXL addiction to liver cancer. Celia Sequera Hurtado (Marseille)	S1CA25: Single-cell analysis of patient-derived organoids reveals treatment-induced clonal dynamics in pancreatic cancer. Vladimir Chocloff (Marseille)

POSTERS SESSION 1

THURSDAY FEBRUARY 5 - 13H00-14H30

Precision oncology, targeted therapies and strategies for refined drug delivery

S1CA12: Lipid and cell cycling perturbations driven by the HDAC inhibitor romidepsin render liver cancer vulnerable to RTK targeting and immunologically active. <i>Margherita Grattarola (Marseille)</i>	S1CA26: Kinetic analysis of nanobody binding to integral membrane proteins on extracellular vesicles. <i>Oksana Reznichenko (Vénissieux)</i>
S1CA13: Deciphering the mechanism of action of ML-IAP and its inhibitors in glioblastoma: towards therapeutic optimization. <i>Théo Vialatte (Marseille)</i>	S1CA27: Repositioning metabolic drugs to target metabolic pathways promoting chemoresistance in pancreatic adenocarcinoma. <i>Afaf Hamame (Marseille)</i>
S1CA14: Diagnostic and Therapeutic Potential of Nanobodies against ADAMTSL5 to Target Cancer Communities. <i>Saliha Lagsier (Marseille)</i>	S1CA28: The ROSALIND Study: Revealing the Cellular and Spatial Architecture of Exceptional Cancer Survival to Enable Therapeutic Discovery. <i>Julieta Rodriguez (Villejuif)</i>

POSTERS SESSION 2

FRIDAY FEBRUARY 6 - 12H20-14H00

Cellular crosstalk and molecular mechanisms of cancer progression

S2CA29: Bystander killing of antigen-negative tumor cells by CD8 CAR-T cells in patient-derived colorectal organoids. <i>Raphael Merand (Villejuif)</i>	S2CA43: Multi-omics profiling uncovers immune-molecular clusters with distinct chemo-immunotherapeutic vulnerabilities in a mouse model of triple-negative breast cancer. <i>Nathan Corvaisier (Marseille)</i>
S2CA30: Deciphering the Role of FAN1 in Chemoresistance to Anthracycline/Taxane Therapy in Breast Cancer. <i>Román Martí Díaz (Spain)</i>	S2CA44: A human pathophysiological 3D-bone marrow model reveals immune and stromal cell heterogeneity. <i>Gulia Campione (Lyon)</i>
S2CA31: How does o-glycosylation drive topological inversion and cell surface expression of calnexin? <i>Haiyang Dong (Marseille)</i>	S2CA45: KRAS allelic imbalance reveals adaptive metabolic states in pancreatic cancer. <i>Alex Chauvin (Marseille)</i>
S2CA32: GALNT: localisation reshapes the glycoproteome in pancreatic cancer and activates integrin beta 1. <i>Eugénie Lohmann (Marseille)</i>	S2CA46: Role of the WNT/PCP CELSR2 receptor in triple-negative breast cancer progression. <i>Julia Koren (Marseille)</i>
S2CA33: The tumour lung microenvironment affects the functional properties and the expression of immune-checkpoints of endothelial cells: an in vitro study to reverse such unfavourable conditioned milieu. <i>Laura Finato (Parma, Italy)</i>	S2CA48: Analysis of automated phosphopeptide enrichment capacity. <i>Emilie Baudalet (Marseille)</i>
S2CA34: A Novel Lineage Tracing System to Reconstruct the Early Steps of Breast Tumorigenesis. <i>Shuheng Lin (Marseille)</i>	S2CA49: PTK7 identifies a regulatory dendritic cell state and is modulated in inflammation and cancer. <i>Lisy Collette (Marseille)</i>

POSTERS SESSION 2

FRIDAY FEBRUARY 6 - 12H20-14H00

Cellular crosstalk and molecular mechanisms of cancer progression

S2CA35: Heme acts as a molecular degrader linking CRL2FEM1B to substrate proteolysis and ferroptosis regulation in lung cancer. Bashir Ahmed (Marseille)	S2CA50: Effects of GALA on the secretion of proteins in liver cancer. Sahar El Amrani (Marseille)
S2CA36: Melanoma-reprogrammed fibroblasts promote tumor progression and immune evasion in the lymph node niche. Melissa Chapeau (Nice)	S2CA51: NUPR1 - Taking Control of Iron Metabolism to Target PDAC. Emma Cosialls (Marseille)
S2CA37: Role of the BMP pathway in mammary stem cells transformation and basal-like breast cancer initiation. Boris Guyot (Lyon)	S2CA52: Glutaminase mechanosensitive glutamylation in breast cancer. Célia Jardin (Marseille)
S2CA38: Investigating the role of PTK7 nuclear localization in Colorectal cancer development. Louis Guiraud (Marseille)	S2CA53: Identify metabolic vulnerabilities that drive dissemination and metastatic expansion of pancreatic ductal adenocarcinoma. Georgios Efthymiou (Marseille)
S2CA39: Determination of the structure of the extracellular domain of the PTK7 receptor by cryo-electron microscopy to unveil its biological functions. Jules Caron (Marseille)	S2CA54: Hyper O-glycosylation drives cell competition in liver tumors. Saba Goodarzi (Marseille)
S2CA40: Syntenin orchestrates matrix degradation by controlling MT1-MMP secretion in small extracellular vesicles and invadopodia formation. Sylvie Thuault (Marseille)	S2CA55: In vitro model to study Circulating Tumor Cells metastatic potential. Léa Girondier, Claire Acquaviva (Marseille)
S2CA41: Function and Regulation of Protein Tyrosine Kinase-7 in Dendritic Cells. Lisy Collette (Marseille)	
S2CA42: Unravelling the role of Ptk7 in hepatic carcinogenesis. Guillaume Desandre (Marseille)	

Partners

We thank our partners and sponsors for their support.

INSTITUTIONAL PARTNERS



SILVER SPONSORS



BRONZE SPONSORS



CRCM

CANCER RESEARCH CENTER

Marseille



VILLE DE
MARSEILLE

OFFICE DE
TOURISME
LOISIRS
& CONGRÈS
MARSEILLE

MEMBRE DES COMités
AU-MARSEILLE
PROVENCE!

This event is supported by the City of Marseille.



GENERAL ORGANIZATION : MCO Congrès - Villa Gaby - 285 Corniche JF Kennedy - 13007 Marseille
Registrations : Audrey Soulier - audrey.soulier@mcocongres.com
Sponsors : Claire Bernard - claire.bernard@mcocongres.com